Vaxart, Precigen among biotech gainers after Q3 results
Source: SeekingAlpha
2025-11-14 14:06:21 ET
More on Vaxart, Precigen
- Precigen, Inc. (PGEN) Q3 2025 Earnings Call Transcript
- Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript
- The Outlook For Precigen
- Vaxart extends cash runway into Q2 2027 with Dynavax partnership and targets 2026 data readouts
- Precigen Q3 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Vaxart, Precigen among biotech gainers after Q3 results
Precigen Inc.
NASDAQ: PGEN
PGEN Trading
4.34% G/L:
$3.475 Last:
1,226,008 Volume:
$3.32 Open:
PGEN Latest News
March 11, 2026 04:05:00 pm
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
January 20, 2026 08:05:00 am
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
January 12, 2026 08:00:00 am
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026 04:05:00 pm
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
PGEN Stock Data
$1,632,900,063
187,173,160
1.3%
60
N/A
Biotechnology & Life Sciences
Healthcare
US
Germantown
